Anti-NXP2 antibody-positive dermatomyositis developed after COVID-19 manifesting as type I interferonopathy.
- Resource Type
- Case Study
- Source
Rheumatology . Apr2022, Vol. 61 Issue 4, pe90-e92. 3p.- Subject
- *
AUTOANTIBODIES
*METHYLPREDNISOLONE
*DERMATOMYOSITIS
*COVID-19
*FEVER
*INTRAVENOUS therapy
*NUCLEAR proteins
*PATIENTS
*CREATINE kinase
*HOSPITAL admission & discharge
*ITCHING
*ELECTROMYOGRAPHY
*DISEASE risk factors - Language
- ISSN
- 1462-0324